Archives
Anlotinib Hydrochloride Suppresses Angiogenesis via Multi-Ki
2026-04-30
Anlotinib Hydrochloride Suppresses Angiogenesis via Multi-Kinase Inhibition
Study Background and Research Question
Angiogenesis—the formation of new blood vessels from pre-existing vasculature—is a key process in both physiological development and pathological states such as tumor progression. Solid tumors rely on angiogenesis to secure nutrients and oxygen, making the inhibition of new vessel formation a central strategy in cancer therapy. The molecular drivers of tumor angiogenesis include vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), and platelet-derived growth factor-BB (PDGF-BB), which activate respective receptors VEGFR2, FGFR1, and PDGFRβ, triggering downstream signaling pathways vital for endothelial cell migration, proliferation, and tube formation (paper). Despite the clinical utility of several small-molecule tyrosine kinase inhibitors (TKIs), there remains a need for more potent and selective anti-angiogenic agents with favorable safety profiles.Key Innovation from the Reference Study
The investigated study introduces anlotinib hydrochloride as a novel multi-target tyrosine kinase inhibitor capable of simultaneously suppressing VEGFR2, PDGFRβ, and FGFR1 activity. Unlike prior agents targeting single or limited kinases, anlotinib demonstrates nanomolar inhibitory potency across all three angiogenic receptors. Notably, its anti-angiogenic effect surpasses that of established drugs such as sunitinib, sorafenib, and nintedanib. Mechanistically, anlotinib reduces receptor phosphorylation and downstream ERK signaling, leading to a comprehensive blockade of pro-angiogenic pathways (paper).Methods and Experimental Design Insights
The research employed an integrated series of in vitro and in vivo assays to dissect anlotinib's anti-angiogenic action. Key methodologies included:- Wound Healing and Directional Migration Assays: Human endothelial cells (EA.hy 926) were exposed to VEGF, PDGF-BB, or FGF-2 to stimulate migration, with and without anlotinib treatment. Migration was quantified by measuring closure of the wound gap and directional transwell migration (paper).
- Capillary Tube Formation Assay: Endothelial cells seeded on Matrigel matrices were assessed for their ability to form capillary-like structures upon growth factor stimulation in the presence or absence of anlotinib (paper).
- Rat Aortic Ring and Chicken Chorioallantoic Membrane (CAM) Assays: These ex vivo and in vivo models evaluated microvessel sprouting and density, providing physiologically relevant evidence of anti-angiogenic efficacy (paper).
- Western Blotting: Used to assess phosphorylation status of VEGFR2, PDGFRβ, FGFR1, and downstream ERK, quantifying pathway inhibition at the molecular level (paper).
Protocol Parameters
- capillary tube formation assay | 5.6–11.7 nM (IC₅₀ for VEGFR2/PDGFRβ/FGFR1) | human EA.hy 926 endothelial cells | Defines effective concentration window for multi-receptor inhibition | paper
- endothelial cell migration inhibition | 5–20 nM (dose-dependent) | in vitro, EA.hy 926 cells | Quantifies migration suppression at nanomolar levels | paper
- rat aortic ring microvessel sprouting | 10–100 nM | ex vivo angiogenesis model | Ensures physiologically relevant anti-angiogenic potency | paper
- ERK signaling pathway inhibition | measurable at ≥10 nM | Western blot, cell lysate | Direct mechanistic evidence for pathway suppression | paper
- cytotoxicity threshold | ≤1 μM (no significant toxicity) | suitable for functional and mechanistic assays | Prevents confounding cell death during angiogenesis studies | product_spec
Core Findings and Why They Matter
The study demonstrated several key findings:- Anlotinib significantly inhibited VEGF/PDGF-BB/FGF-2-induced migration and tube formation in endothelial cells, with IC₅₀ values in the low nanomolar range (source: paper).
- In both the rat aortic ring and CAM assays, anlotinib markedly reduced neovessel sprouting and microvessel density, supporting its anti-angiogenic potential in complex tissue environments (paper).
- Comparative analysis revealed that anlotinib outperformed sunitinib, sorafenib, and nintedanib in inhibiting angiogenesis (paper).
- Mechanistically, anlotinib potently blocked phosphorylation of VEGFR2, PDGFRβ, and FGFR1, and downstream ERK activation, effectively shutting down the pro-angiogenic signaling cascade (paper).
- Importantly, these effects occurred without significant cytotoxicity at functional concentrations, supporting selective anti-angiogenic action (source: product_spec).
Comparison with Existing Internal Articles
Internal resources further contextualize these findings:- The article at angiotensin-1-7.com collates benchmark data on anlotinib's nanomolar inhibition of VEGFR2, PDGFRβ, and FGFR1, aligning with the reference study's potency claims.
- GSKChem highlights advanced workflow compatibility and reproducibility in tumor angiogenesis assays, reinforcing the practical utility of anlotinib for both mechanistic and translational research.
- For protocol guidance and troubleshooting, the resource at mubritinibrx.com describes stepwise assay implementation using anlotinib, supporting the reference paper's methodological rigor.
Limitations and Transferability
While the study’s in vitro and in vivo models provide robust evidence for anlotinib’s anti-angiogenic properties, several caveats must be considered:- The main experimental systems focus on endothelial and vascular models; direct tumor microenvironment complexity and inter-patient variability in clinical contexts require further exploration (paper).
- Pharmacokinetic and safety profiles, though favorable in preclinical studies (source: product_spec), may differ in specific tumor types or comorbid conditions.
- Transferability from rat and chicken models to human systems, while supported by conserved pathway blockade, merits further validation in humanized or patient-derived models (workflow_recommendation).